Stockscreener 앱 받기
0.8399
4.78%
0.0383
전일 마감가:
$0.8016
열려 있는:
$0.8
하루 거래량:
106.19K
Relative Volume:
0.56
시가총액:
$32.77M
수익:
$135.87M
순이익/손실:
$72.20M
주가수익비율:
0.5915
EPS:
1.42
순현금흐름:
$45.09M
1주 성능:
-2.90%
1개월 성능:
+10.51%
6개월 성능:
-25.01%
1년 성능:
-51.45%
1일 변동 폭
$0.7945
$0.8499
1주일 범위
$0.7945
$0.90
52주 변동 폭
$0.66
$1.79
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
SCYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.8399 | 31.28M | 135.87M | 72.20M | 45.09M | 1.42 |
|
ZTS
Zoetis Inc
|
154.11 | 67.83B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.00 | 46.74B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.86 | 20.12B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
313.13 | 14.11B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-22 | 개시 | Guggenheim | Buy |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-11 | 업그레이드 | Needham | Hold → Buy |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-10 | 개시 | ROTH Capital | Buy |
| 2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
| 2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-20 | 개시 | H.C. Wainwright | Buy |
| 2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2016-08-17 | 개시 | Guggenheim | Buy |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 개시 | Brean Capital | Buy |
| 2015-12-29 | 개시 | WBB Securities | Speculative Buy |
| 2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-06-10 | 개시 | Needham | Buy |
| 2014-05-29 | 개시 | Canaccord Genuity | Buy |
| 2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
SCYNEXIS Inc. stock retracement – recovery analysis2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
Is SCYNEXIS Inc. stock poised for growth2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
Real time scanner hits for SCYNEXIS Inc. explainedEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Scynexis reports Q2 EPS (14c), consensus (19c) - MSN
Historical volatility pattern of SCYNEXIS Inc. visualizedTrade Ideas & Daily Stock Momentum Reports - Newser
What candlestick patterns are forming on SCYNEXIS Inc.July 2025 Closing Moves & Consistent Income Trade Ideas - Newser
SCYNEXIS Reports Improved Financials Amidst Strategic Developments - MSN
Scynexis Posts Q2 2025 Earnings Miss; Market Resilience Observed Post-Report - AInvest
Can SCYNEXIS Inc. hit a new high this monthMarket Risk Analysis & High Conviction Investment Ideas - Newser
Key metrics from SCYNEXIS Inc.’s quarterly dataWeekly Profit Report & Expert Curated Trade Setup Alerts - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attention2025 Buyback Activity & Daily Profit Focused Screening - Newser
SCYNEXIS Inc. stock trend forecastIPO Watch & Low Drawdown Investment Strategies - Newser
Will a bounce in SCYNEXIS Inc. offer an exit2025 Pullback Review & Long Hold Capital Preservation Tips - Newser
SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Scynexis 2025 Q2 Earnings Significant Loss Reduction - AInvest
Sector ETF performance correlation with SCYNEXIS Inc.2025 Big Picture & Long-Term Growth Stock Strategies - Newser
How high can SCYNEXIS Inc. stock goPrice Action & Growth Focused Investment Plans - Newser
What’s next for SCYNEXIS Inc. stock priceJuly 2025 Rallies & Safe Capital Allocation Plans - Newser
Scynexis: Q2 Earnings Snapshot - Stamford Advocate
SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment - MSN
SCYNEXIS Inc. Earnings Report Breakdown: What Investors Should KnowMarket Movement Recap & Safe Entry Momentum Tips - Newser
Scynexis Inc earnings beat by $0.06, revenue topped estimates - Investing.com India
SCYNEXIS Doses First Patient in Phase 3 MARIO Study, $10M Milestone Payment Triggered Amid Ongoing Dispute with GSK - Quiver Quantitative
SCYNEXIS Restarts Key Phase 3 Trial but Faces Payment Dispute with Partner GSK over $30M Milestone - Stock Titan
Price momentum metrics for SCYNEXIS Inc. explainedWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
Using Python tools to backtest SCYNEXIS Inc. strategiesMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Chartists See Breakout Potential in SCYNEXIS Inc.Low Risk Swing Trade Opportunities Identified - 선데이타임즈
Technical analysis overview for SCYNEXIS Inc. stockFree Fundamental Winners With Safe Entry Plan - Newser
Reviewing CytoDyn (OTCMKTS:CYDY) & SCYNEXIS (NASDAQ:SCYX) - Defense World
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.80%
0.22%
자본화:
|
볼륨(24시간):